Linni Klaus, Ugurluoglu Ara, Aspalter Manuela, Hitzl Wolfgang, Hölzenbein Thomas
Department of Vascular and Endovascular Surgery, Paracelus Medizinische Privatuniversität (PMU), Salzburg, Austria.
Department of Vascular and Endovascular Surgery, Paracelus Medizinische Privatuniversität (PMU), Salzburg, Austria.
J Vasc Surg. 2016 Feb;63(2):391-8. doi: 10.1016/j.jvs.2015.08.081. Epub 2015 Oct 19.
The aim of this study was to compare the clinical and hemodynamic outcomes of plain vs paclitaxel-coated percutaneous transluminal angioplasty (PTA) in patients with infrainguinal vein bypass stenosis.
A single-center retrospective analysis was conducted of consecutive patients treated by infrainguinal bypass PTA. Primary study end points were primary and assisted primary patency. Secondary end points were clinical and hemodynamic improvement, limb salvage, and survival. Society for Vascular Surgery reporting standards were applied.
From April 2008 to November 2014, 83 infrainguinal vein bypasses were treated for graft stenosis by plain (group A, n = 41) or by paclitaxel-coated PTA (group B, n = 42). The groups did not differ significantly in mean age (71.9 years for both groups; P = .99), hypertension (P = 1.0), hyperlipidemia (P = .5), diabetes (P = .6), coronary artery disease (P = 1.0), smoking (P = 1.0), preoperative ankle-brachial index (P = .08), or bypass characteristics (below-knee, P = .82). Technical success rate was 100% for both groups. Mean follow-up was 2.9 years for group A patients and 2.2 years for group B patients (P = .08). No patient was lost to follow-up. Primary patency rates were 88% vs 87% and 73% vs 75% (P = .19) and assisted primary patency rates were 88% vs 90% and 77% vs 84% (P = .76) for group A and B patients at 1 and 2 years, respectively. Repeat target lesion revascularization rates were 22% vs 14% (P = .17). At the last follow-up, there were eight vs seven bypass occlusions (P = .74) for group A and B patients, respectively. In univariate analysis, proximal in-graft stenosis (Cox F, P = .041), bypass failure <6 months after bypass surgery (Cox F, P = .013), more than one bypass stenosis per graft (Cox F, P = .047), and redo bypass procedure (Cox F, P = .0001) were significantly related to assisted primary bypass patency. Immediate hemodynamic and sustained clinical improvement rates were 88% vs 86% and 70% vs 73% for group A and B patients, respectively. There were three vs one major amputations (P = .36) and eight vs seven deaths (P = .78) in group A and B patients, respectively.
Paclitaxel-coated and plain angioplasty of significant infrainguinal vein bypass stenoses performed equally well in clinical and hemodynamic improvement and in primary and assisted primary bypass patency rates.
本研究旨在比较单纯经皮腔内血管成形术(PTA)与紫杉醇涂层PTA治疗腹股沟下静脉搭桥狭窄患者的临床和血流动力学结局。
对接受腹股沟下搭桥PTA治疗的连续患者进行单中心回顾性分析。主要研究终点为主要通畅率和辅助主要通畅率。次要终点为临床和血流动力学改善、肢体挽救和生存率。采用血管外科学会报告标准。
2008年4月至2014年11月,83例腹股沟下静脉搭桥患者因移植物狭窄接受单纯PTA(A组,n = 41)或紫杉醇涂层PTA治疗(B组,n = 42)。两组患者的平均年龄(均为71.9岁;P = 0.99)、高血压(P = 1.0)、高脂血症(P = 0.5)、糖尿病(P = 0.6)、冠状动脉疾病(P = 1.0)、吸烟(P = 1.0)、术前踝肱指数(P = 0.08)或搭桥特征(膝下,P = 0.82)无显著差异。两组技术成功率均为100%。A组患者平均随访2.9年,B组患者平均随访2.2年(P = 0.08)。无患者失访。A组和B组患者1年和2年时的主要通畅率分别为88%对87%和73%对75%(P = 0.19),辅助主要通畅率分别为88%对90%和77%对84%(P = 0.76)。再次靶病变血运重建率分别为22%对14%(P = 0.17)。在最后一次随访时,A组和B组患者分别有8例和7例搭桥闭塞(P = 0.74)。单因素分析显示,移植物近端狭窄(Cox F,P = 0.041)、搭桥术后<6个月搭桥失败(Cox F,P = 0.013)、每个移植物有一个以上搭桥狭窄(Cox F,P = 0.047)和再次搭桥手术(Cox F,P = 0.0001)与辅助主要搭桥通畅率显著相关。A组和B组患者的即时血流动力学和持续临床改善率分别为88%对86%和70%对73%。A组和B组患者分别有3例和1例大截肢(P = 0.36),8例和7例死亡(P = 0.78)。
在临床和血流动力学改善以及主要和辅助主要搭桥通畅率方面,紫杉醇涂层和单纯血管成形术治疗严重的腹股沟下静脉搭桥狭窄效果相当。